BLEOMYCIN A6

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C60H96N20O21S2
Molecular Weight	1497.656
Optical Activity	UNSPECIFIED
Defined Stereocenters	19 / 19
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]3O)C4=CN=CN4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCNCCCCNCCCN

InChI

InChIKey=FOUFFVYWFNBHHH-YNGSZULRSA-N

InChI=1S/C60H96N20O21S2/c1-25-38(77-51(80-49(25)64)30(17-36(63)84)72-18-29(62)50(65)90)55(94)79-40(46(31-19-69-24-73-31)99-59-48(44(88)42(86)34(20-81)98-59)100-58-45(89)47(101-60(66)96)43(87)35(21-82)97-58)56(95)74-27(3)41(85)26(2)52(91)78-39(28(4)83)54(93)71-16-9-37-75-33(23-102-37)57-76-32(22-103-57)53(92)70-15-8-14-68-12-6-5-11-67-13-7-10-61/h19,22-24,26-30,34-35,39-48,58-59,67-68,72,81-83,85-89H,5-18,20-21,61-62H2,1-4H3,(H2,63,84)(H2,65,90)(H2,66,96)(H,69,73)(H,70,92)(H,71,93)(H,74,95)(H,78,91)(H,79,94)(H2,64,77,80)/t26-,27+,28+,29-,30-,34-,35+,39-,40-,41-,42+,43+,44-,45-,46-,47-,48-,58+,59-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C60H96N20O21S2
Molecular Weight	1497.656
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	19 / 19
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12567444 | https://adisinsight.springer.com/drugs/800009288 | https://www.ncbi.nlm.nih.gov/pubmed/26460847

Bleomycin A6 (also known as boanmycin) was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer. It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. The development of this drug, apparently, was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Bleomycin A6-loaded anionic liposomes with in situ gel as a new antitumoral drug delivery system.	2016	24845479
[Inhibitory effect of bleomycin A6 on human colon cancer xenografts in nude mice].	1990-10	1714798
[Preclinical pharmacologic evaluation of bleomycin A6].	1989-07	2483136

Sample Use Guides

In Vivo Use Guide

Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:07:33 GMT 2025` Edited by `admin` on `Mon Mar 31 21:07:33 GMT 2025`
Record UNII	0B19OCB220
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BLEOMYCINAMIDE, N(SUP 1)-(3-((4-((3-AMINOPROPYL)AMINO)BUTYL)AMINO)PROPYL)-

Preferred Name

English

BLEOMYCIN A6

Common Name

English

ZHENGGUANGMYCIN A6

Common Name

English

PINGYANGMYCIN A6

Common Name

English

N(SUP 1)-(3-((4-((3-AMINOPROPYL)AMINO)BUTYL)AMINO)PROPYL)BLEOMYCINAMIDE

Common Name

English

Bleomycin A6 [WHO-DD]

Common Name

English

BOANMYCIN

Common Name

English

BLEOMYCINAMIDE, N1-(3-((4-((3- AMINOPROPYL)AMINO)BUTYL)AMINO)PROPYL)-

Common Name

English

Code System Code Type Description

SMS_ID

300000019152